NewAmsterdam Pharma (NAMS) Debt to Equity (2022 - 2025)
NewAmsterdam Pharma's Debt to Equity history spans 4 years, with the latest figure at $0.08 for Q4 2025.
- For Q4 2025, Debt to Equity rose 69.21% year-over-year to $0.08; the TTM value through Dec 2025 reached $0.08, up 69.21%, while the annual FY2025 figure was $0.08, 69.21% up from the prior year.
- Debt to Equity for Q4 2025 was $0.08 at NewAmsterdam Pharma, up from $0.06 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.08 in Q4 2025 and bottomed at $0.01 in Q4 2022.
- The 4-year median for Debt to Equity is $0.05 (2024), against an average of $0.05.
- The largest annual shift saw Debt to Equity skyrocketed 419.72% in 2023 before it tumbled 62.31% in 2025.
- A 4-year view of Debt to Equity shows it stood at $0.01 in 2022, then surged by 419.72% to $0.04 in 2023, then grew by 13.59% to $0.05 in 2024, then skyrocketed by 69.21% to $0.08 in 2025.
- Per Business Quant, the three most recent readings for NAMS's Debt to Equity are $0.08 (Q4 2025), $0.06 (Q3 2025), and $0.03 (Q2 2025).